Grunnleggende statistikk
| CIK | 1111485 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to RxSight, Inc.
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2025 |
Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Aliso Viejo, Calif. (Nasdaq: RXST) – August 7, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights • Reported second quarter 202 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 4, 2025 |
RXSIGHT, INC. APPOINTS RAYMOND W. COHEN TO ITS BOARD OF DIRECTORS Exhibit 99.1 RXSIGHT, INC. APPOINTS RAYMOND W. COHEN TO ITS BOARD OF DIRECTORS Aliso Viejo, Calif., (Nasdaq: RXST) August 4, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. “We are thrilled to welcome Raymond W. Cohe |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 8, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 8, 2025 |
RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance Exhibit 99.1 RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) – July 8, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-y |
|
| June 4, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT RxSight, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-40690 94-3268801 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) 100 Columbia Aliso Viejo, California 92656 (Address of prin |
|
| May 20, 2025 |
RxSight, Inc. Conflict Minerals Report as required by Items 1.01 of this Form SD. Annex A RxSight, Inc. 2024 Facility and Country List Metal Smelter Name Country Compliance Status Gold 8853 S.p.A. ITALY Unknown Gold ABC Refinery Pty Ltd. AUSTRALIA Unknown Gold Abington Reldan Metals, LLC UNITED STATES OF AMERICA Conformant Gold Advanced Chemical Company UNITED STATES OF AMERICA Conformant Gold African Gold Refinery UGANDA Unknown Gold Agosi AG GERMANY Conformant Gold Aida Chemi |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2025 |
Exhibit 99.1 RXSIGHT, INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – May 7, 2025– RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights • Reported first quarter 2025 r |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 3, 2025 |
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance Exhibit 99.1 RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) – April 2, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 02, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 25, 2025 |
2021 Equity Incentive Plan, and form agreements thereunder Exhibit 10.3 RxSIGHT, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s business. (b) Award Types. T |
|
| February 25, 2025 |
Exhibit 19.1 RXSIGHT, INC. INSIDER TRADING POLICY (Adopted on July 1, 2021 and effective as of the Company’s initial public offering; amended as of March 2, 2023 and October 31, 2024) A. POLICY OVERVIEW RxSight, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and r |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40690 RxSight, Inc. ( |
|
| February 25, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 RxSight, Inc. (the “Company,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) – our common stock, par value $0.001 per share (“common stock”). Description of Common Stock |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) RxSight, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation on Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee rate Amount of Registration Fee Equity Common Stock, $0.001 par valu |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 |
Outside Director Compensation Policy Exhibit 10.33 RxSIGHT, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved July 1, 2021 as amended December 19, 2024 RxSight, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of t |
|
| February 25, 2025 |
Exhibit 99.1 RXSIGHT, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS, REAFFIRMS 2025 GUIDANCE Aliso Viejo, Calif. (NASDAQ: RXST) – February 25, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 3 |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 25, 2025 |
Exhibit 10.13 SEVENTH AMENDMENT (EXTENSION TO THE LEASE) THIS INSTRUMENT (hereinafter referred to as the “Seventh Amendment”), dated the 25th day of October, is entered into by ACCURIDE INTERNATIONAL INC., a California corporation (hereinafter referred to as “Landlord”) and RXSIGHT, Inc. (formerly known as CALHOUN VISION, INC.), a Delaware corporation, (hereinafter referred to as “Tenant”). The pa |
|
| January 13, 2025 |
Exhibit 99.1 RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) – January 12, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financi |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 14, 2024 |
EX-99.1 2 tm2427451d25ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi |
|
| November 14, 2024 |
RXST / RxSight, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d25sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* RxSIGHT, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78349D107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 12, 2024 |
RXST / RxSight, Inc. / Artisan Partners Limited Partnership - SC 13G/A Passive Investment SC 13G/A 1 d777631dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 1 )* RxSight, Inc. (Name of Issuer) Common Stock (Title of Class |
|
| November 12, 2024 |
EX-99.1 2 d777631dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 11/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTI |
|
| November 7, 2024 |
Exhibit 10.1 Amendment # 3 to the Sublease Agreement THIS 3rd AMENDMENT TO THE SUBLEASE AGREEMENT (hereinafter referred to as “Amendment”) is made and entered into effective August 1, 2024 (the “Amendment Effective Date”), by and between RxSight, Inc., a Delaware corporation (“RxSight”), and Compass Bible Church (“Sublessee”, and together with RxSight, the “Parties”). WHEREAS, the Parties entered |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| November 7, 2024 |
Exhibit 99.1 RXSIGHT, INC. REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – November 7, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights • Reported third quar |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 5, 2024 |
Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – August 5, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024. Key Quarterly Highlights • Reported second quarter 2 |
|
| August 5, 2024 |
Exhibit 10.4 FIFTH AMENDMENT (EXTENSION TO THE LEASE) THIS Amendment (hereinafter referred to as the “Fifth Amendment”), dated the 18th day of April 2024, is entered into by ACCURIDE INTERNATIONAL INC., a California corporation (hereinafter referred to as “Landlord”) and RXSIGHT, Inc., a Delaware corporation, (hereinafter referred to as “Tenant”). The parties agree as follows: A. Identification of |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 5, 2024 |
Exhibit 10.5 SIXTH AMENDMENT THIS Amendment (hereinafter referred to as the “Sixth Amendment”), dated the 3rd day of June 2024, is entered into by ACCURIDE INTERNATIONAL INC., a California corporation (hereinafter referred to as “Landlord”) and RXSIGHT, Inc., a Delaware corporation, (hereinafter referred to as “Tenant”). The parties agree as follows: A. Identification of Lease. Reference is made t |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| August 5, 2024 |
Exhibit 10.2 LEASE AMENDMENT #2 (5 Columbia, Aliso Viejo, CA 92656) This 2nd Amendment to the Lease Agreement (hereinafter referred to as “Amendment”) is made and entered into by and between Clifford D. Downs (the “Lessor”) and RxSight, Inc., a Delaware Corporation (the “Lessee”, and together with Lessor, the “Parties”) as the last date signed by the Parties (the “Effective Date”). WHEREAS, the Pa |
|
| August 5, 2024 |
Exhibit 10.3 LEASE AMENDMENT #3 (5 Columbia, Aliso Viejo, CA 92656) This 3rd Amendment to the Lease Agreement (hereinafter referred to as “Amendment”) is made and entered into by and between Clifford D. Downs (the “Lessor”) and RxSight, Inc., a Delaware Corporation (the “Lessee”, and together with Lessor, the “Parties”) as the last date signed by the Parties (the “Effective Date”). WHEREAS, the Pa |
|
| August 5, 2024 |
Exhibit 10.6 Amendment # 3 to the Sublease Agreement THIS 3rd AMENDMENT TO THE SUBLEASE AGREEMENT (hereinafter referred to as “Amendment”) is made and entered into effective August 1, 2024 (the “Amendment Effective Date”), by and between RxSight, Inc., a Delaware corporation (“RxSight”), and Compass Bible Church (“Sublessee”, and together with RxSight, the “Parties”). WHEREAS, the Parties entered |
|
| August 5, 2024 |
Exhibit 10.1 STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NET (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1.Basic Provisions ("Basic Provisions"). 1.1 Parties. This Lease ("Lease"), dated for reference purposes only April 5, 2024 , is made by and between BML Management, LLC ("Lessor") and RxSight, Inc. ("Lessee"), (collectively the "Parties," or individually a "Party"). 1.2 Premises: |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT RxSight, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40690 94-3268801 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) 100 Columbia Aliso Viejo, California 92656 (Address of principa |
|
| May 16, 2024 |
RxSight, Inc. Conflict Minerals Report as required by Items 1.01 of this Form SD. Annex A RxSight, Inc. 2023 Facility and Country List Metal Smelter Name Country Compliance Status Gold 8853 S.p.A. Italy Unknown Gold ABC Refinery Pty Ltd. Australia Unknown Gold Abington Reldan Metals, LLC United States Of America Conformant Gold Advanced Chemical Company United States Of America Active Gold African Gold Refinery Uganda Unknown Gold Agosi AG Germany Conformant Gold Aida Chemical |
|
| May 9, 2024 |
RxSight, Inc. Announces Pricing of Public Offering of Common Stock Exhibit 99.1 RxSight, Inc. Announces Pricing of Public Offering of Common Stock Aliso Viejo, Calif. (NASDAQ: RXST) – May 8, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common |
|
| May 9, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279206 PROSPECTUS SUPPLEMENT (To Prospectus dated May 8, 2024) 1,785,714 Shares We are offering an aggregate of 1,785,714 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “RXST.” On May 8, 2024, the last reported sale price of our shares |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) RxSight, Inc. |
|
| May 9, 2024 |
Exhibit 1.1 RxSight, Inc. 1,785,714 Shares of Common Stock, par value $0.001 per share Underwriting Agreement May 8, 2024 BofA Securities, Inc. As Representative of the several Underwriters listed in Schedule 1 hereto BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: RxSight, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 8, 2024 |
SUBJECT TO COMPLETION, DATED MAY 8, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279206 This preliminary prospectus supplement and accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying pros |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 8, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2024 Registration No. |
|
| May 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RxSight, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate (4) Amount of Registration F |
|
| May 6, 2024 |
Exhibit 99.1 RXSIGHT, INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) – May 6, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights • Reported first quarter 2024 |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) RxSight, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation on Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee rate Amount of Registration Fee Equity Common Stock, $0.001 par valu |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
Outside Director Compensation Policy Exhibit 10.27 RxSIGHT, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved July 1, 2021 as amended December 14, 2023 RxSight, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of t |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 28, 2024 |
Exhibit 97.1 RXSIGHT, INC. COMPENSATION RECOVERY POLICY As adopted on November 1, 2023 RxSight, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-for-performance philos |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40690 RxSight, Inc. ( |
|
| February 28, 2024 |
Exhibit 99.1 RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – February 28, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023. Key Quarterly and |
|
| February 14, 2024 |
RXST / RxSight, Inc. / LORD, ABBETT & CO. LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* RxSIGHT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78349D107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2024 |
RXST / RxSight, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* RxSIGHT, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78349D107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 14, 2024 |
EX-99.1 2 tm246065d17ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 12, 2024 |
EX-99.1 2 d755022dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTIS |
|
| February 12, 2024 |
RXST / RxSight, Inc. / Artisan Partners Limited Partnership - SC 13G Passive Investment SC 13G 1 d755022dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. )* RxSight Inc (Name of Issuer) Common Stock (Title of Class of Securities) 78349D1 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 07, 2024 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 8, 2024 |
Exhibit 99.1 RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) – January 7, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financia |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 9, 2023 |
Exhibit 99.1 RxSight, Inc. Reports Third Quarter 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – November 9, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights • Reported t |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| August 18, 2023 |
RXST / RxSight Inc / Longitude Capital Partners II, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) RXSIGHT, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78349D107 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854- |
|
| August 7, 2023 |
Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RXSIGHT, INC. a Delaware corporation RxSight, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on July 1, 2021. B. This Amended a |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2023 |
Exhibit 99.1 RxSight, Inc. Reports Second Quarter 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – August 7, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights • Reported second q |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| July 5, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to tim |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 5, 2023 |
RXST / RxSight Inc / Longitude Capital Partners II, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) RXSIGHT, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78349D107 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854- |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2023 |
Exhibit 99.1 RxSight, Inc. Reports First Quarter 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – May 9, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2023. Key Quarterly Highlights • Reported first quarter 2023 |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 6, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) RxSight, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation on Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee rate Amount of Registration Fee Equity Common Stock, $0.001 par valu |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 6, 2023 |
Exhibit 99.1 RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – March 6, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2022. Key Quarterly and Ful |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. |
|
| March 6, 2023 |
Executive Incentive Compensation Plan Exhibit 10.35 RxSIGHT, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Executives to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payable to a Part |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40690 RxSight, Inc. ( |
|
| March 6, 2023 |
Exhibit 10.18 Amendment # 2 to Sublease Agreement THIS 2nd AMENDMENT TO SUBLEASE AGREEMENT (hereinafter referred to as “Amendment”) is made and entered into effective January 4, 2023 (the “Amendment Effective Date”), by and between RxSight, Inc., a Delaware corporation (“RxSight”), and Compass Bible Church (“Sublessee”, and together with RxSight, the “Parties”). WHEREAS, the Parties entered into t |
|
| February 14, 2023 |
EX-99 2 ss1758614ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of RxSight, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Ex |
|
| February 14, 2023 |
RXST / RxSight, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss1758614sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 RxSight, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78349D107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 8, 2023 |
RxSight, Inc. Announces Pricing of Public Offering of Common Stock EX-99.1 Exhibit 99.1 RxSight, Inc. Announces Pricing of Public Offering of Common Stock Aliso Viejo, Calif. (NASDAQ: RXST) – February 7, 2023 – RxSight, Inc. (“RxSight”), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 4,000,000 shares of its c |
|
| February 8, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266651 PROSPECTUS SUPPLEMENT (To Prospectus dated August 12, 2022) 4,000,000 shares We are offering an aggregate of 4,000,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “RXST.” On February 7, 2023, the last reported sale price of ou |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 8, 2023 |
EX-1.1 2 d426433dex11.htm EX-1.1 Exhibit 1.1 RxSight, Inc. 4,000,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement February 7, 2023 BofA Securities, Inc. As Representative of the several Underwriters listed in Schedule 1 hereto One Bryant Park New York, New York 10036 Ladies and Gentlemen: RxSight, Inc., a Delaware corporation (the “Company”), proposes to issue and sell |
|
| February 7, 2023 |
SUBJECT TO COMPLETION, DATED FEBRUARY 7, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266651 This preliminary prospectus supplement and accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying pros |
|
| January 9, 2023 |
EX-99.1 2 rxst-ex991.htm EX-99.1 Exhibit 99.1 RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results Aliso Viejo, Calif. (NASDAQ: RXST) – January 8, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced certain preliminary unaudited financial and |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2023 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 12, 2022 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF RXSIGHT, INC. (initially adopted on July 1, 2021) (as amended and restated on August 3, 2021, as further amended on December 9, 2022) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANC |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| November 7, 2022 |
Exhibit 99.1 RxSight, Inc. Reports Third Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – November 7, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2022. Key Quarterly Highlights: • Delivered third quarter 2022 |
|
| August 12, 2022 |
Common Stock Preferred Stock Debt Securities Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266651 PROSPECTUS $200,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may issue securities from time to time in one or more offerings, in amounts, at prices and on terms determined at the time of offering. This prospectus describes the general terms of these securities and the general manner in which th |
|
| August 10, 2022 |
August 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: John Conlon Danberg Re: RxSight, Inc. Registration Statement on Form S-3 Filed August 8, 2022 File No. 333-266651 Acceleration Request Requested Date: August 12, 2022 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| August 8, 2022 |
RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million Exhibit 99.1 RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program Aliso Viejo, Calif. (NASDAQ: RXST) ? August 8, 2022 ? RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it has filed a $200 million shelf registration statement on Form S-3 with |
|
| August 8, 2022 |
Exhibit 99.1 RxSight, Inc. Reports Second Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) ? August 8, 2022 ? RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2022. Key Quarterly Highlights: ? Delivered second quarter 2022 revenu |
|
| August 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RxSight, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| August 8, 2022 |
Exhibit 4.3 RXSIGHT, INC. INDENTURE Dated as of , 20 [TRUSTEE NAME] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment o |
|
| August 8, 2022 |
EX-1.2 2 d383901dex12.htm EX-1.2 Exhibit 1.2 RxSight, Inc. Common Stock ($0.001 par value) ATM EQUITY OFFERINGSM SALES AGREEMENT August 8, 2022 BofA Securities, Inc. c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: RxSight, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time t |
|
| August 8, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 8, 2022 |
Exhibit 10.1 Amendment # 1 to Sublease Agreement THIS 1st AMENDMENT TO CONSULTING AGREEMENT (hereinafter referred to as ?Amendment?) is made and entered into effective June 1, 2022 (the ?Amendment Effective Date?), by and between RxSight, Inc., a Delaware corporation (?RxSight?), and Compass Bible Church (?Sublessee?, and together with RxSight, the ?Parties?). WHEREAS, the Parties entered into tha |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| July 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2022 |
Exhibit 10.2 LEASE ADDENDUM The following shall be deemed added to the Lease Agreement dated January 10, 2018, by and between Clifford D. Downs (Lessor) and RxSight, Inc., a Delaware Corporation (Lessee) for the property located at 5 Columbia, Aliso Viejo, CA 92656, with an effective date of April 5, 2022. 1. Lessor and Lessee agree to a 24-month lease extension effective April 1, 2023, and ending |
|
| May 5, 2022 |
Exhibit 99.1 RxSight, Inc. Reports First Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – May 5, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended March 31, 2022. Key Quarterly Highlights: • Delivered first quarter 2022 revenue of $8.9 mi |
|
| May 5, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| May 5, 2022 |
Exhibit 10.1 SUBLEASE FOR MULTIPLE TENANTS To be used if there will be one or more sublessees sharing the space with each other and/or the lessee, whether or not the space (Premises) is a single tenant building or is located in a multi-tenant building. If the entire space (Premises) will be subleased by a single sublessee, whether or not the space (Premises) is a single tenant building or is locat |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-4 |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 08, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 8, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 8, 2022, RxSight, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?) ? our common stock, par value $0.001 per share (?common stock?). Description of Common Stock The following de |
|
| March 8, 2022 |
EX-99.1 2 rxst-ex991.htm EX-99.1 Exhibit 99.1 RxSight, Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) – March 8, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months and fiscal year ended December 31, 2021. Rece |
|
| March 8, 2022 |
As filed with the Securities and Exchange Commission on March 8, 2022 Registration No. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40690 RxSight, Inc. ( |
|
| March 8, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) RxSight, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value p |
|
| March 8, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary State/Country of Incorporation/Organization RxSight B.V. Netherlands RxSight GmbH Germany |
|
| March 8, 2022 |
Exhibit 10.28 STANDARD INDUSTRIAL/COMMERCIAL MULTI?TENANT LEASE ? NET 1. Basic Provisions ("Basic Provisions"). 1.1 Parties. This Lease ("Lease"), dated for reference purposes only March 4, 2022 , is made by and between BML Management, LLC ("Lessor") and RxSight, Inc. ("Lessee"), (collectively the "Parties", or individually a "Party"). 1.2(a) Premises: That certain real property, including all imp |
|
| February 14, 2022 |
RXST / RxSight, Inc. / RxSight I, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RxSight, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78349D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2022 |
Exhibit 99.1 AGREEMENT OF JOINT FILING This joint filing agreement (this ?Agreement?) is made and entered into as of this 14th day of February 2022, by and among H.I.G. BioVentures ? Calhoun, LLC, H.I.G.-GPII, Inc., Anthony Tamer, and Sami Mnaymneh. The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Schedule 13 |
|
| February 14, 2022 |
RXST / RxSight, Inc. / TAMER ANTHONY - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RxSight, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 78349D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 14, 2022 |
RXST / RxSight, Inc. / Wolfen Richard M. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. )1 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 RXSIGHT, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 78349D107 (CUSIP Number) |
|
| February 14, 2022 |
Exhibit 99.1 AGREEMENT OF JOINT FILING In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common |
|
| February 11, 2022 |
RXST / RxSight, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 RxSight, Inc. |
|
| February 11, 2022 |
CUSIP No. 78349D107 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, $0.001 par value per share, of RxSight, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities E |
|
| January 10, 2022 |
Exhibit 99.1 RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results Aliso Viejo, Calif., January 9, 2022 (GLOBE NEWSWIRE) - (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced preliminary unaudited financial and operational results for |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2022 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 4, 2022 |
Exhibit 99.1 RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors Aliso Viejo, Calif., (NASDAQ: RXST) January 4, 2022 ? RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, MD and Shweta Singh Maniar to its Board of Directo |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 10, 2021 |
2021 Equity Incentive Plan of the registrant, as amended, and forms of agreement thereunder. Exhibit 10.2 RxSIGHT, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, ?Service Providers?), and to promote the success of the Company?s business. (b) Award Types. T |
|
| November 10, 2021 |
Exhibit 99.1 RxSight Reports Third Quarter 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) ? November 10, 2021 ? RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended September 30, 2021. Recent Highlights ? Achieved third quarter 2021 revenue of $5.8 million |
|
| November 10, 2021 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RXSIGHT, INC. a Delaware corporation RxSight, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on July 1, 2021. B. This Amended a |
|
| November 10, 2021 |
2021 Employee Stock Purchase Plan of the registrant. exhibit 10.3 RxSIGHT, Inc. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Code Section 42 |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 9, 2021 |
Exhibit 99.1 RxSight Reports Second Quarter 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) ? September 9, 2021 ? RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended June 30, 2021. Recent Highlights ? Achieved second quarter 2021 revenue of $4.9 million, r |
|
| September 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 09, 2021 RxSight, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40690 94-3268801 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40690 RxSIGHT, INC. |
|
| August 13, 2021 |
RXST / RxSight, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RxSIGHT, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 78349D107 (CUSIP Number) August 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| August 13, 2021 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of August 13, 2021, is by and among RA Capital Management, L. |
|
| August 13, 2021 |
Joint Filing Agreement, dated August 13, 2021, by and among the Reporting Persons (filed herewith). EX-99.1 2 d221322dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| August 13, 2021 |
RXST / RxSight, Inc. / Longitude Capital Partners II, LLC - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) RXSIGHT, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 78349D107 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners II, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (650) 854-5700 (Name |
|
| July 30, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257790 Prospectus 7,350,000 Shares Common stock This is the initial public offering of shares of common stock by RxSight, Inc. We are offering 7,350,000 shares of our common stock to be sold in this offering. Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for li |
|
| July 30, 2021 |
As filed with the Securities and Exchange Commission on July 30, 2021 Registration No. |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 RXSIGHT INC. (Exact name of registrant as specified in its charter) Delaware 94-3268801 (State of incorporation or organization) (I.R.S. Employer Identification No.) 100 Columbia Aliso Viejo, CA 92 |
|
| July 28, 2021 |
As filed with the Securities and Exchange Commission on July 27, 2021. Table of Contents As filed with the Securities and Exchange Commission on July 27, 2021. |
|
| July 28, 2021 |
Form of Underwriting Agreement, including Form of Lock-up Agreement. Exhibit 1.1 RxSight, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting Agreement [●], 2021 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen |
|
| July 27, 2021 |
July 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Tim Buchmiller Tracey Houser Daniel Gordon Re: RxSight, Inc. Registration Statement on Form S-1 File No. 333-257790 Acceleration Request Requested Date: July 29, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and G |
|
| July 27, 2021 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 BofA Securities, Inc. One Bryant Park New York, New York 10036 July 27, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: RxSight, Inc. Registration Statement on Form S-1, as amended (File No. 333-257790) Request for Acceleration of Effective Dat |
|
| July 26, 2021 |
2015 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 10.2 Calhoun Vision, Inc. 2015 Equity Incentive Plan TABLE OF CONTENTS Page Article 1. Establishment, Objectives, and Duration 1 Article 2. Definitions 1 Article 3. Administration 5 Article 4. Shares Subject to the Plan and Maximum Awards 5 Article 5. Eligibility and Participation 7 Article 6. Stock Options 7 Article 7. Stock Appreciation Rights 9 Article 8. Restricted Stock and Stock Awar |
|
| July 26, 2021 |
Specimen common stock certificate of the Registrant Exhibit 4.2 The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the Corporatio |
|
| July 26, 2021 |
2021 Equity Incentive Plan, and form agreements thereunder EX-10.3 6 d237930dex103.htm EX-10.3 Exhibit 10.3 RxSIGHT, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Co |
|
| July 26, 2021 |
Consent to be Named as a Director Nominee (Robert Warner). Exhibit 99.1 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by RxSight, Inc. of the Registration Statement on Form S-1, and in all subsequent amendments and post-effective amendments or supplements thereto, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securitie |
|
| July 26, 2021 |
Exhibit 10.27 SHARE FORFEITURE AND RELEASE AGREEMENT THIS SHARE FORFEITURE AND RELEASE AGREEMENT (this “Agreement”) is made and entered into as of July 23, 2021 (the “Effective Date”) by and among RXSIGHT, INC., a Delaware corporation (the “Company”) and DANIEL M. SCHWARTZ, a natural person (“Maker”). RECITALS WHEREAS, the Company made a loan to the Maker in the original principal amount of $160,0 |
|
| July 26, 2021 |
As filed with the Securities and Exchange Commission on July 26, 2021. S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 26, 2021. |
|
| July 26, 2021 |
Form of Underwriting Agreement, including Form of Lock-up Agreement. EX-1.1 2 d237930dex11.htm EX-1.1 Exhibit 1.1 RxSight, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting Agreement [●], 2021 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc. One Bryant Park New York, Ne |
|
| July 26, 2021 |
Consent to be Named as a Director Nominee (Julie B. Andrews). EX-99.2 13 d237930dex992.htm EX-99.2 Exhibit 99.2 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by RxSight, Inc. of the Registration Statement on Form S-1, and in all subsequent amendments and post-effective amendments or supplements thereto, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, |
|
| July 26, 2021 |
EX-10.6 8 d237930dex106.htm EX-10.6 Exhibit 10.6 CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 6, 2021 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 2231 |
|
| July 26, 2021 |
Consent to be Named as a Director (Robert J. Palmisano). EX-99.3 14 d237930dex993.htm EX-99.3 Exhibit 99.3 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by RxSight, Inc. of the Registration Statement on Form S-1, and in all subsequent amendments and post-effective amendments or supplements thereto, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, |
|
| July 26, 2021 |
2021 Employee Stock Purchase Plan and form agreements thereunder Exhibit 10.4 RxSIGHT, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under Code Section 42 |
|
| July 26, 2021 |
EX-10.24 9 d237930dex1024.htm EX-10.24 Exhibit 10.24 TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this “Agreement”) is effective as of the closing of the Public Offering (as defined below), by and between RxSight, Inc., a Delaware corporation (“Company”), and Yelroc Consulting, Inc., an entity (“Consultant”). All capitalized terms used but not defined herein shall have the corresponding meani |
|
| July 22, 2021 |
*FOIA Confidential Treatment Request* Confidential Treatment Requested by RxSight, Inc. |
|
| July 9, 2021 |
EX-10.17 20 d237930dex1017.htm EX-10.17 Exhibit 10.17 July 8, 2021 Ilya Goldshleger c/o RxSight, Inc. 100 Columbia, Aliso Viejo, CA 92656 Re: Confirmatory Employment Letter Dear Ilya: This letter agreement (the “Agreement”) is entered into between Ilya Goldshleger (“you”) and RxSight, Inc. (the “Company” or “we”). This Agreement is effective as of July 16, 2021 . The purpose of this Agreement is t |
|
| July 9, 2021 |
EX-10.1 7 d237930dex101.htm EX-10.1 Exhibit 10.1 RXSIGHT, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of and is between RxSight, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS WHEREAS, indemnitee’s service to the Company substantially benefits the Company. WHEREAS, individuals are reluctant to |
|
| July 9, 2021 |
Exhibit 10.7 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and CALHOUN VISION, INC. for SILICONE INTRAOCULAR LENSES EMBEDDED WITH PHOTOSENSITIVE COMPOSITIONS (SF99-076) and METHODS AN |
|
| July 9, 2021 |
Exhibit 10.23 RXSIGHT, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made by and between RxSight, Inc. (the “Company”), and Daniel M. Schwartz, MD (the “Consultant”), in the state of California, effective January 1st, 2019. 1. Services. The Consultant shall provide to the Company the services set forth in paragraph 1 of Exhibit A in accordance with the terms and conditio |
|
| July 9, 2021 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 12235 El Camino Real San Diego, California 92130-3002 o: 858. |
|
| July 9, 2021 |
EX-3.2 3 d237930dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RXSIGHT, INC. a Delaware corporation RxSight, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware o |
|
| July 9, 2021 |
Power of Attorney (see page II-7 to this Form S-1). Table of Contents As filed with the Securities and Exchange Commission on July 9, 2021. |
|
| July 9, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. EX-3.1 2 d237930dex31.htm EX-3.1 Exhibit 3.1 Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF “RXSIGHT, INC.”, FILED IN THIS OFFICE ON THE FIRST DAY OF JULY, A.D. 2021, AT 2:55 O` CLOCK P.M. /s/ Jeffrey W. Bullock Jeffrey W. Bullock, Secretary of State |
|
| July 9, 2021 |
Exhibit 10.11 COMMERCIAL LEASE AGREEMENT BETWEEN ACCURIDE INTERNATIONAL, INC. a California corporation as Landlord and Calhoun Vision, Inc. a California corporation as Tenant Dated: October 27, 2015 Columbia Corporate Center Aliso Viejo, California TABLE OF CONTENTS ARTICLE 1 BASIC LEASE PROVISIONS 2 ARTICLE 2 TERM AND POSSESSION 4 ARTICLE 3 RENT 6 ARTICLE 4 SECURITY DEPOSIT 8 ARTICLE 5 OCCUPANCY |
|
| July 9, 2021 |
EX-10.10 13 d237930dex1010.htm EX-10.10 Exhibit 10.10 CLOUD SERVICES AGREEMENT This Cloud Services Agreement is made effective on May 28, 2021 between: QAD Inc., having its principal place of business at 100 Innovation Place, CA 93108 Santa Barbara, United States (hereinafter “Vendor”), and RxSight, Inc. having its principal place of business at 100 Columbia, Aliso Viejo, CA 92656 (hereinafter “Cu |
|
| July 9, 2021 |
EX-10.12 15 d237930dex1012.htm EX-10.12 Exhibit 10.12 LEASE AGREEMENT (INDUSTRIAL/COMMERCIAL SINGLE-TENANT) 1. Basic Provisions (“Basic Provisions”). 1.1. Parties. This Lease (“Lease”), dated for reference purposes only March 27, 2020, is made by and between Pacific Park Investments, Inc., a California corporation (“Lessor”) and RxSight, Inc., a California corporation (“Lessee”), (collectively the |
|
| July 9, 2021 |
Exhibit 10.20 RXSIGHT, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made between RxSight, Inc. (the “Company”) and Eric J. Weinberg (the “Executive”), effective as of July 16, 2021 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection w |
|
| July 9, 2021 |
Exhibit 10.16 July 8, 2021 Eric J. Weinberg c/o RxSight, Inc. 100 Columbia, Aliso Viejo, CA 92656 Re: Confirmatory Employment Letter Dear Eric: This letter agreement (the “Agreement”) is entered into between Eric J. Weinberg (“you”) and RxSight, Inc. (the “Company” or “we”). This Agreement is effective as of July 16, 2021 . The purpose of this Agreement is to confirm the terms and conditions of yo |
|
| July 9, 2021 |
EX-4.1 6 d237930dex41.htm EX-4.1 Exhibit 4.1 RXSIGHT, INC. NINTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT FEBRUARY 24, 2017 TABLE OF CONTENTS Page SECTION 1. GENERAL 2 1.1 Amendment and Restatement 2 1.2 Definitions 2 SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER 6 2.1 Restrictions on Transfer 6 2.2 S-1 Demand Registration 7 2.3 Piggyback Registrations 8 2.4 Form S-3 Registration 9 2.5 |
|
| July 9, 2021 |
EX-10.5 8 d237930dex105.htm EX-10.5 Exhibit 10.5 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of October 29, 2020 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 2 |
|
| July 9, 2021 |
Exhibit 10.15 July 8, 2021 Shelley B. Thunen c/o RxSight, Inc. 100 Columbia, Aliso Viejo, CA 92656 Re: Confirmatory Employment Letter Dear Shelley: This letter agreement (the “Agreement”) is entered into between Shelley B. Thunen (“you”) and RxSight, Inc. (the “Company” or “we”). This Agreement is effective as of July 16, 2021 . The purpose of this Agreement is to confirm the terms and conditions |
|
| July 9, 2021 |
EX-10.18 21 d237930dex1018.htm EX-10.18 Exhibit 10.18 RXSIGHT, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made between RxSight, Inc. (the “Company”) and Ron Kurtz (the “Executive”), effective as of July 16, 2021 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control |
|
| July 9, 2021 |
EX-10.22 25 d237930dex1022.htm EX-10.22 Exhibit 10.22 RXSIGHT, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made by and between RxSight, Inc. (the “Company”), and Yelroc Consulting, Inc. (the “Consultant”), in the state of California, effective January 1st, 2019. 1. Services. The Consultant shall provide to the Company the services set forth in paragraph 1 of Exhibit A |
|
| July 9, 2021 |
EX-10.24 27 d237930dex1024.htm EX-10.24 Exhibit 10.24 AMENDED AND RESTATED SECURED FULL RECOURSE PROMISSORY NOTE (This Amended and Restated Secured Full Recourse Promissory Note (the “Note”) supersedes in its entirety that certain Secured Full Recourse Promissory Note dated as of April 18, 2016 (the “Original Note”), previously representing the indebtedness set forth below, which previous Note sha |
|
| July 9, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF RXSIGHT, INC. (initially adopted on [ ]) (as amended and restated on [ ], 2021) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 8 |
|
| July 9, 2021 |
Exhibit 10.21 RXSIGHT, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made between RxSight, Inc. (the “Company”) and Ilya Goldshleger (the “Executive”), effective as of July 16, 2021 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection w |
|
| July 9, 2021 |
EXHIBIT 10.8 LICENSE AND MAINTENANCE AGREEMENT This license and maintenance agreement (“Agreement”) is made effective October 29, 2015 between: QAD Inc., having its principal place of business at 100 Innovation Place, Santa Barbara, CA 93108 USA (hereinafter “QAD”), and Calhoun Vision, Inc. having its principal place of business at 171 North Altadena Drive, Suite 201, Pasadena, CA 91107 (hereinaft |
|
| July 9, 2021 |
Amended and Restated Bylaws of the Registrant, as currently in effect. Exhibit 3.3 BYLAWS OF RXSIGHT, INC. Adopted July 1, 2021 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Record Dates 4 1.11 Prox |
|
| July 9, 2021 |
Exhibit 10.9 Developed for: Calhoun Vision 171 N. Altadena Dr., Suite 201 Pasadena, CA 91107 Date: October 16, 2015 By: Strategic Information Group 1953 San Elijo Avenue, Suite 201 Cardiff-by-the-Sea, CA 92007 USA Phone: 760-697-1050 Expires: October 31, 2015 Revision: Calhoun Vision QAD ERP Hosted On Premise Proposal 151016-02 Calhoun Vision EE SOW On Premise 150920-03.xls Strategic Information G |
|
| July 9, 2021 |
EX-10.13 16 d237930dex1013.htm EX-10.13 Exhibit 10.13 STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - NET (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1. Basic Provisions (“Basic Provisions”). 1.1 Parties. This Lease (“Lease”), dated for reference purposes only January 10, 2018. is made by and between Clifford D, Downs (“Lessor”) and RxSight, Inc., a California corporation (“Lessee”), (c |
|
| July 9, 2021 |
Exhibit 10.6 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. LICENCE AGREEMENT THIS AGREEMENT is effective as of the 28th day of July, 2015 (the “Effective Date”), between the CALIFORNIA INSTITUTE OF TECHNOLOGY (“Caltech”), a not-for-profit corporation duly organiz |
|
| July 9, 2021 |
Exhibit 10.19 RXSIGHT, INC. CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made between RxSight, Inc. (the “Company”) and Shelley B. Thunen (the “Executive”), effective as of July 16, 2021 (the “Effective Date”). This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection |
|
| July 9, 2021 |
Exhibit 10.14 July 8, 2021 Ron Kurtz c/o RxSight, Inc. 100 Columbia, Aliso Viejo, CA 92656 Re: Confirmatory Employment Letter Dear Ron: This letter agreement (the “Agreement”) is entered into between Ron Kurtz (“you”) and RxSight, Inc. (the “Company” or “we”). This Agreement is effective as of July 16, 2021. The purpose of this Agreement is to confirm the terms and conditions of your employment. 1 |
|
| June 24, 2021 |
DRS/A 1 filename1.htm Table of Contents Amendment No. 1 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on June 23, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE |
|
| June 23, 2021 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 12235 El Camino Real San Diego, California 92130-3002 o: 858. |
|
| May 17, 2021 |
DRS 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 17, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRA |
